Laboratories seeking to buy CJC-1295 without DAC for preclinical research require verified purity, lot-specific analytics, and precise peptide synthesis. As a modified growth hormone-releasing hormone (GHRH) analog, CJC-1295 without DAC is widely investigated in cellular and animal models for its ability to stimulate physiological growth hormone pulsatility and downstream IGF-1 levels. PX1 Research supplies high-purity, research-grade CJC-1295 without DAC manufactured under strict quality standards with independent analytical verification.
Laboratories seeking to buy CJC-1295 without DAC for preclinical research require verified purity, lot-specific analytics, and precise peptide synthesis. As a modified growth hormone-releasing hormone (GHRH) analog, CJC-1295 without DAC is widely investigated in cellular and animal models for its ability to stimulate physiological growth hormone pulsatility and downstream IGF-1 levels. PX1 Research supplies high-purity, research-grade CJC-1295 without DAC manufactured under strict quality standards with independent analytical verification.
When purchasing CJC-1295 without DAC for analytical testing or cellular assays, verifying chemical structure, sequence integrity, and purity profiles is paramount. CJC-1295 without DAC—often referred to in the literature as Mod GRF 1-29—is a synthetic 29-amino-acid peptide derived from the native GHRH(1-29) sequence, modified at four specific amino acid positions to resist rapid enzymatic clearance by dipeptidyl peptidase-IV (DPP-IV). Unlike its conjugated counterpart featuring Drug Affinity Complex (DAC), the non-DAC variant does not covalently bind to serum albumin, resulting in a significantly shorter biological half-life that closely mimics the natural physiological pulses of endogenous GHRH.
In preclinical settings, researchers evaluate this compound to understand pituitary somatotroph signaling, pulse kinetics, and downstream endocrine cascades. To maintain reproducibility across experimental trials, institutions must source material verified via high-performance liquid chromatography (HPLC) and mass spectrometry (MS). PX1 Research provides research facilities with fully documented, highly purified compounds manufactured in compliance with ISO 17025 analytical standards.
CJC-1295 without DAC functions as a selective agonist at the GHRH receptor (GHRHR), a G-protein-coupled receptor located on the cell membrane of anterior pituitary somatotrophs. Binding of the peptide activates the Gs alpha subunit, triggering adenylate cyclase to convert ATP into cyclic adenosine monophosphate (cAMP). This intracellular rise in cAMP activates protein kinase A (PKA), leading to the phosphorylation of transcription factors such as CREB and opening voltage-gated calcium channels.
The influx of extracellular calcium drives the exocytosis of stored growth hormone (GH) vesicles into the systemic environment. Preclinical studies suggest that because CJC-1295 without DAC lacks the albumin-binding complex, receptor activation remains transient. This allows somatotrophs to return to baseline sensitivity between stimuli, preserving the natural episodic pulsatility of pituitary secretion rather than inducing continuous, non-physiological elevation.
Understanding the structural and pharmacokinetic differences between GHRH variants is essential when selecting compounds for specific experimental models. The primary distinction lies in the presence or absence of the Lys(Maleimidopropionyl) modification at the C-terminus.
CJC-1295 with DAC incorporates a reactive maleimide group that forms a stable covalent bond with endogenous circulating albumin following administration. This modification extends the plasma half-life in rodent models from minutes to several days, creating continuous GHRH receptor occupancy. Conversely, CJC-1295 without DAC exhibits a half-life of approximately 30 minutes in animal models. This rapid clearance profile makes the non-DAC variant ideal for assays examining acute physiological GH releases, pulsatile signaling, and receptor desensitization kinetics without causing long-term downregulation of GHRH receptors.
In secretagogue research, investigators frequently evaluate dual-pathway stimulation by combining GHRH analogs with growth hormone secretagogue receptor (GHSR-1a) agonists. While GHRH analogs like Mod GRF 1-29 activate the cAMP/PKA pathway, GHSR agonists recruit the phospholipase C (PLC) and inositol triphosphate (IP3) signaling pathways.
In vitro data indicate that co-incubating somatotroph cultures with CJC-1295 without DAC and a selective GHSR agonist produces a synergistic release of GH that exceeds the additive effects of either compound tested individually. Research models often utilize Ipamorelin alongside CJC-1295 without DAC to explore maximal somatotroph response while avoiding unwanted increases in cortisol or prolactin secretion. For comprehensive comparative models, researchers can explore our full range of growth hormone secretagogues.
Preclinical studies evaluating GHRH analogs demonstrate consistent upregulation of systemic insulin-like growth factor-1 (IGF-1) secondary to transient GH elevation. In animal models of tissue injury, elevated IGF-1 signaling correlates with accelerated cellular proliferation, increased collagen synthesis, and enhanced nitrogen retention in musculoskeletal structures.
Rodent assays focused on metabolic performance suggest that pulsatile GH secretion induced by CJC-1295 without DAC supports free fatty acid mobilization and lipid oxidation while preserving glycogen stores. Because the non-DAC variant avoids continuous baseline GHRH stimulation, researchers observe sustained IGF-1 bioactivity without inducing receptor desensitization or altering baseline pituitary sensitivity over extended observational periods.
When designing end-point secretagogue protocols, selecting the precise compound profile is crucial. Investigators evaluating GHRH receptor targets often compare CJC-1295 without DAC, Sermorelin, and CJC-1295 with DAC to map structural stability against receptor affinity.
While Sermorelin represents the native 1-29 amino acid sequence, it remains highly vulnerable to DPP-IV enzymatic cleavage, resulting in a half-life under 12 minutes in rodent serum. The four amino acid substitutions in CJC-1295 without DAC (D-Ala2, Gln8, Ala15, Leu27) provide superior enzymatic stability without altering receptor target selectivity. Contrastingly, CJC-1295 with DAC extends exposure to days, altering the biological feedback loop. Researchers analyzing secretagogue mechanisms can review detailed comparative breakdowns in our CJC-1295 vs Ipamorelin study overview.
The integrity of preclinical data depends strictly on the purity of the chemical reagents utilized. Impurities such as truncated peptide fragments, residual coupling reagents, or organic solvents can disrupt cellular assays and yield erratic baseline measurements. PX1 Research enforces rigorous quality control protocols across all catalog items.
Every batch of CJC-1295 without DAC undergoes Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm chemical purity exceeding 99%, alongside Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular weight. Additionally, bacterial endotoxin testing (LAL assay) is conducted to ensure endotoxin levels remain below strictly defined limits for sensitive cell culture and in vivo applications. Every product ships with a lot-specific Certificate of Analysis (COA) directly downloadable from our peptide research hub.
CJC-1295 without DAC is supplied as a lyophilized (freeze-dried) sterile powder to ensure long-term chemical stability. For optimal shelf-life, unopened vials should be stored at -20°C in a desiccated environment away from light. Prior to reconstitution, vials should be allowed to equilibrate to room temperature to prevent condensation inside the container.
For laboratory reconstitution, researchers typically utilize Bacteriostatic Water (0.9% benzyl alcohol) or sterile physiological saline depending on the downstream assay requirements. Solvents should be introduced gently down the inner glass wall of the vial, followed by mild swirl agitation—never vigorous shaking—to prevent mechanical shear stress and peptide denaturation. Reconstituted solutions should be stored at 2°C to 8°C and utilized within published experimental stability windows.
Procuring research compounds demands supplier transparency, consistent manufacturing standards, and rapid fulfillment. PX1 Research synthesizes compounds in state-of-the-art US-based facilities compliant with cGMP frameworks and ISO 17025 laboratory quality management system guidelines.
Orders are dispatched directly from our dual logistics facilities in California and Arizona, offering same-day shipping on business days for minimal transit latency. Principal investigators and procurement officers managing large-scale screening projects or institutional accounts can access specialized volume tiers through our dedicated wholesale lab account portal or browse our complete catalog at the PX1 Research catalog.
What is CJC-1295 without DAC?
CJC-1295 without DAC (Mod GRF 1-29) is a synthetic 29-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH). It features four modified amino acids that enhance resistance to DPP-IV enzymatic degradation while maintaining rapid enzymatic clearance compared to DAC-bound variants.
What is the difference between CJC-1295 with DAC and CJC-1295 without DAC?
The key difference is the half-life and secretion pattern. CJC-1295 with DAC contains a Drug Affinity Complex that binds serum albumin, extending its biological half-life to several days and producing continuous GHRH elevation. CJC-1295 without DAC lacks this complex, yielding a shorter half-life (~30 minutes) that simulates natural, pulsatile GHRH release.
What preclinical research is CJC-1295 without DAC used for?
In preclinical research, CJC-1295 without DAC is studied for its ability to stimulate growth hormone release, evaluate IGF-1 axis upregulation, analyze tissue repair pathways, and investigate synergistic secretagogue dynamics when co-administered with GHRPs.
How does PX1 Research verify the purity of CJC-1295 without DAC?
Every lot undergoes independent third-party analytical testing using RP-HPLC for purity (>99%) and mass spectrometry (ESI-MS) for molecular weight confirmation. Endotoxin assays are also conducted. Lot-specific Certificates of Analysis (COAs) are made available to purchasing institutions.
How should lyophilized CJC-1295 without DAC be stored in the lab?
Lyophilized powder should be stored at -20°C in a dry, dark environment. Once reconstituted with an appropriate solvent like bacteriostatic water, the liquid peptide solution should be stored at 2°C to 8°C and used within standard experimental protocol timelines.
Where are PX1 Research compounds manufactured and shipped from?
All PX1 Research compounds are manufactured in US-based facilities adherence to strict quality control guidelines. Shipments dispatch directly from our California and Arizona distribution hubs with same-day processing for orders placed before standard daily cutoffs.
Is CJC-1295 without DAC approved for human consumption or therapeutic use?
No. CJC-1295 without DAC provided by PX1 Research is sold strictly for in vitro, cellular, and preclinical laboratory research use only. It is not for human or animal therapeutic use, clinical administration, or household consumption.
Can CJC-1295 without DAC be combined with other peptides in cellular assays?
Yes, in preclinical research protocols, CJC-1295 without DAC is frequently co-evaluated with growth hormone secretagogue receptor agonists such as Ipamorelin to study dual-pathway somatotroph activation and biological synergy.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.